NeuroBo Pharmaceuticals (NRBO) just unveiled an update.
NeuroBo Pharmaceuticals, Inc. has successfully passed a First Amendment to its 2022 Equity Incentive Plan, following approval from the Board and the company’s stockholders. This amendment paves the way for an annual automatic increase in the number of shares available for awards, starting from January 2025, and also raises the cap on shares for Incentive Stock Options. Moreover, the Annual Meeting saw the election of three directors, the ratification of the company’s independent auditor, and a solid shareholder turnout, indicating strong engagement and decisive action in shaping the company’s future.
Find detailed analytics on NRBO stock on TipRanks’ Stock Analysis page.
